INDV

Over the past six months, Indivior's stock price has been impacted by several events. The company reported strong first-quarter 2026 results, raising its full-year financial guidance, which contributed to a significant increase in the stock price. Indivior completed its redomiciliation to the U.S. in January 2026. In February 2026, Indivior initiated a share repurchase program of up to $400 million and completed a $500 million convertible senior notes offering in April 2026. Indivior announced the cessation of internal development for two OUD drug candidates in April 2026. In November 2025, the company concluded a legacy Department of Justice matter with a $295 million payment.